LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Akcijų sąrašas・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

18.54 0.87

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.12

Max

18.76

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-607K -51M
Pardavimai	-28M 100M
Pelnas, tenkantis vienai akcijai	-0.46
Pelno marža	-51.215
Darbuotojai	1,784
EBITDA	4.1M -44M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+75.61% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-308M 2.1B
Ankstesnė atidarymo kaina	17.67
Ankstesnė uždarymo kaina	18.54

Naujienos nuotaikos

By Acuity

30%

70%

59 / 344 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-27 21:33; UTC

Uždarbis

Correction to Salesforce 1Q Sales, Profit Rise Article

2026-05-27 21:00; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Agrees to Buy The College of Health Care Professions

2026-05-27 20:18; UTC

Uždarbis

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

2026-05-27 23:49; UTC

Rinkos pokalbiai

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

2026-05-27 23:39; UTC

Rinkos pokalbiai

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-27 23:08; UTC

Rinkos pokalbiai

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

2026-05-27 22:21; UTC

Rinkos pokalbiai

Salesforce Lays Out AI Monetization Strategy -- Market Talk

2026-05-27 21:29; UTC

Karštos akcijos

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

2026-05-27 21:08; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

2026-05-27 21:02; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

2026-05-27 20:59; UTC

Įsigijimai, susijungimai, perėmimai

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

2026-05-27 20:55; UTC

Uždarbis

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

2026-05-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-27 20:48; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

2026-05-27 20:45; UTC

Uždarbis

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

2026-05-27 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Webster Financial Stockholders Approve Sale to Banco Santander

2026-05-27 20:32; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

2026-05-27 20:30; UTC

Uždarbis

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

2026-05-27 20:30; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

2026-05-27 20:22; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:16; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

2026-05-27 20:13; UTC

Uždarbis

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

75.61% į viršų

12 mėnesių prognozė

Vidutinis 32.4 USD 75.61%

Aukščiausias 44 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Zai Lab Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

59 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.